| scholarly article | Q13442814 |
| P50 | author | Michael P. Busch | Q6833284 |
| Brian Edlin | Q43185278 | ||
| Brandee L Pappalardo | Q114440605 | ||
| P2093 | author name string | Sally Caglioti | |
| Leslie H Tobler | |||
| Thomas R O'Brien | |||
| David J Wright | |||
| Teresa L Wright | |||
| Andrew R Moss | |||
| Kimberly Page-Shafer | |||
| Bruce H Phelps | |||
| P2860 | cites work | The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations | Q43048511 |
| Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco | Q43657708 | ||
| Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users | Q44116660 | ||
| National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infection | Q45412803 | ||
| Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. | Q45423068 | ||
| Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment | Q45483691 | ||
| Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China | Q45654072 | ||
| Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City | Q45728900 | ||
| Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment | Q45733180 | ||
| Evidence of hepatitis C virus viremia without detectable antibody to hepatitis C virus in a blood donor | Q45741764 | ||
| Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood‐donor screening | Q46126583 | ||
| Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response | Q63432592 | ||
| Prolonged antibody-negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient | Q73149092 | ||
| Acute hepatitis C | Q73427444 | ||
| Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif | Q73466642 | ||
| Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? | Q81907838 | ||
| Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. | Q27471239 | ||
| High levels of subgenomic HCV plasma RNA in immunosilent infections | Q27481224 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome | Q29620780 | ||
| Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. | Q31052065 | ||
| Tutorial in biostatistics methods for interval-censored data | Q32108424 | ||
| Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study | Q33825988 | ||
| Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients | Q34333821 | ||
| US NAT yield: where are we after 2 years? | Q34830197 | ||
| Global burden of disease (GBD) for hepatitis C. | Q35610002 | ||
| Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies | Q36346436 | ||
| Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. | Q36575203 | ||
| Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda | Q38881073 | ||
| Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. | Q39544134 | ||
| Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center | Q39587059 | ||
| Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. | Q39649363 | ||
| Correlates of hepatitis C virus infections among injection drug users. | Q40453200 | ||
| Failure to diagnose recent hepatitis C virus infections in London injecting drug users | Q40500438 | ||
| Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion | Q42633467 | ||
| Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. | Q42672043 | ||
| Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. | Q42983246 | ||
| Full or partial seroreversion in patients infected by hepatitis C virus | Q42983552 | ||
| HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection | Q42986755 | ||
| Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing | Q42986999 | ||
| Dynamics of viremia in early hepatitis C virus infection | Q42992916 | ||
| Viral and host factors in early hepatitis C virus infection | Q42993098 | ||
| Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. | Q42994569 | ||
| Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus | Q43031089 | ||
| Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. | Q43034863 | ||
| Treatment of acute hepatitis C with interferon alfa-2b | Q43036093 | ||
| Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests | Q43040626 | ||
| Hepatitis C virus seroconversion among young injection drug users: relationships and risks | Q43041146 | ||
| High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. | Q43047625 | ||
| The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy | Q43047736 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 499-506 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates | |
| P478 | volume | 46 |
| Q59349878 | A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs |
| Q42213249 | A prospective study of hepatitis C incidence in Australian prisoners |
| Q33650138 | Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection |
| Q38403672 | Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys |
| Q35118973 | Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report |
| Q35864200 | Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users |
| Q90134557 | Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies |
| Q33631170 | Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens |
| Q57696129 | Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011 |
| Q42980113 | Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations. |
| Q41488562 | Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: a population-level tool for incidence estimation |
| Q92633061 | Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection |
| Q38118578 | Epidemiology and natural history of HCV infection. |
| Q51852529 | Estimating acute viral hepatitis infections from nationally reported cases. |
| Q35832850 | Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study |
| Q56556912 | Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration |
| Q89435945 | Group testing case identification with biomarker information |
| Q91843571 | HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco |
| Q40466502 | Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. |
| Q36148971 | Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study |
| Q47594606 | Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis |
| Q36717008 | Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine |
| Q34101320 | Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index |
| Q34381567 | Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users |
| Q40563923 | Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection. |
| Q37288631 | High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. |
| Q38014990 | Identifying newly acquired cases of hepatitis C using surveillance: a literature review |
| Q33724826 | Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort |
| Q92203757 | Incidence, prevalence and risk factors for hepatitis C in Danish prisons |
| Q34982096 | Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection |
| Q36058580 | Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes |
| Q37042431 | Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention |
| Q34785317 | Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study |
| Q40659995 | Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection |
| Q42996974 | Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots |
| Q43117957 | More rare birds, and the occasional swan |
| Q28476518 | Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users |
| Q35138230 | Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients |
| Q35249648 | Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study |
| Q28540414 | Per-event probability of hepatitis C infection during sharing of injecting equipment |
| Q33824723 | Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users |
| Q51126531 | Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. |
| Q36783211 | Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department |
| Q34028058 | Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions |
| Q36200292 | Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. |
| Q30713067 | Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. |
| Q47564410 | Sensitivity and specificity of a new automated system for the detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus nucleic acid in blood and plasma donations. |
| Q30407004 | Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection |
| Q36433960 | Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification |
| Q37678136 | The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection |
| Q43000782 | The influence of hepatitis C and alcohol on liver-related morbidity and mortality in Glasgow's injecting drug user population. |
| Q35593482 | The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014 |
| Q35910953 | Traceability, reproducibility and clinical evaluation of Sansure Realtime HCV RNA assay |
| Q35551683 | Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012. |
| Q35641523 | Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection |
| Q37855530 | Treatment of acute HCV infection |
| Q40832940 | Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection |
Search more.